Pacira Biosciences (NASDAQ:PCRX) Announces Earnings Results

Pacira Biosciences (NASDAQ:PCRX) issued its quarterly earnings results on Thursday. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.35, Briefing.com reports. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The business had revenue of $104.69 million for the quarter, compared to analysts’ expectations of $104.88 million. During the same period last year, the business earned $0.31 earnings per share. The business’s quarterly revenue was up 25.5% on a year-over-year basis.

Shares of Pacira Biosciences stock traded up $1.40 on Friday, hitting $44.02. The stock had a trading volume of 711,200 shares, compared to its average volume of 631,161. The company has a quick ratio of 4.12, a current ratio of 4.75 and a debt-to-equity ratio of 0.99. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 151.79, a PEG ratio of 1.96 and a beta of 1.13. The stock’s 50-day simple moving average is $39.20 and its two-hundred day simple moving average is $41.12. Pacira Biosciences has a one year low of $34.64 and a one year high of $50.90.

A number of research analysts have commented on the stock. Barclays increased their price target on shares of Pacira Biosciences from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday. BTIG Research assumed coverage on shares of Pacira Biosciences in a research report on Wednesday. They set a “buy” rating and a $56.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price target on shares of Pacira Biosciences in a research report on Thursday. Stifel Nicolaus set a $42.00 price target on shares of Pacira Biosciences and gave the company a “hold” rating in a research report on Friday, August 9th. Finally, BidaskClub upgraded shares of Pacira Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. Pacira Biosciences presently has an average rating of “Hold” and an average price target of $52.55.

In other news, CEO David M. Stack sold 12,849 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $39.15, for a total transaction of $503,038.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kristen Marie Williams sold 6,252 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $39.49, for a total value of $246,891.48. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Story: Benefits of owning preferred stock

Earnings History for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.